Decheng Capital LLC
Q4 2025 13F Holdings
- Locationmenlo park, CA
- Num holdings
19
- Value ($000)
$743,407
- Date Filed02/12/2026
- Form type13F-HR
- CIK0002010850
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
CG ONCOLOGY INC | COM | 156944100 | $264.55M | 36 % | 6,371,669 | ||
Nuvation Bio Inc. | COM | 67080N101 | $232.55M | 31 % | 25,954,439 | ||
Upstream Bio Inc. | COM | 91678A107 | $85.33M | 12 % | 3,143,078 | ||
AARDVARK THERAPEUTICS INC | COM | 002942100 | $51.41M | 7 % | 3,917,299 | ||
Lyell Immunopharma, Inc. | COM | 55083R104 | $21.3M | 3 % | 692,050 | ||
NEWAMSTERDAM PHARMA CO NV | COM | N62509109 | $20.77M | 3 % | 592,057 | ||
REVOLUTION MEDICINES INC(NSM) | COM | 76155X100 | $15.93M | 2 % | 200,000 | ||
Arcus Biosciences, Inc | COM | 03969F109 | $12.91M | 2 % | 541,559 | ||
Aclaris Therapeutics, Inc. | COM | 00461U105 | $12.17M | 2 % | 4,041,736 | ||
Equillium Inc. | COM | 29446K106 | $6.89M | 1 % | 4,447,308 |
Rows Per Page
10
- 5
- 10
- 20
- 30
- 50
- 100